FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160930691> ?p ?o ?g. }

• W2160930691 endingPage "3153" @default.
• W2160930691 startingPage "3148" @default.
• W2160930691 abstract "To investigate the effect of a sustained (7-day) decrease in plasma free fatty acid (FFA) concentrations on insulin action and intramyocellular long-chain fatty acyl-CoAs (LCFA-CoAs), we studied the effect of acipimox, a potent inhibitor of lipolysis, in seven type 2 diabetic patients (age 53 +/- 3 years, BMI 30.2 +/- 2.0 kg/m2, fasting plasma glucose 8.5 +/- 0.8 mmol/l, HbA 1c 7.5 +/- 0.4%). Subjects received an oral glucose tolerance test (OGTT) and 120-min euglycemic insulin (80 mU/m2 per min) clamp with 3-[3H]glucose/vastus lateralis muscle biopsies to quantitate rates of insulin-mediated whole-body glucose disposal (Rd) and intramyocellular LCFA-CoAs before and after acipimox (250 mg every 6 h for 7 days). Acipimox significantly reduced fasting plasma FFAs (from 563 +/- 74 to 230 +/- 33 micromol/l; P < 0.01) and mean plasma FFAs during the OGTT (from 409 +/- 44 to 184 +/- 22 micromol/l; P < 0.01). After acipimox, decreases were seen in fasting plasma insulin (from 78 +/- 18 to 42 +/- 6 pmol/l; P < 0.05), fasting plasma glucose (from 8.5 +/- 0.8 to 7.0 +/- 0.5 mmol/l; P < 0.02), and mean plasma glucose during the OGTT (from 14.5 +/- 0.8 to 13.0 +/- 0.8 mmol/l; P < 0.05). After acipimox, insulin-stimulated Rd increased from 3.3 +/- 0.4 to 4.4 +/- 0.4 mg x kg(-1) x min(-1) (P < 0.03), whereas suppression of endogenous glucose production (EGP) was similar and virtually complete during both insulin clamp studies (0.16 +/- 0.10 vs. 0.14 +/- 0.10 mg x kg(-1) x min(-1); P > 0.05). Basal EGP did not change after acipimox (1.9 +/- 0.2 vs. 1.9 +/- 0.2 mg x kg(-1) x min(-1)). Total muscle LCFA-CoA content decreased after acipimox treatment (from 7.26 +/- 0.58 to 5.64 +/- 0.79 nmol/g; P < 0.05). Decreases were also seen in muscle palmityl CoA (16:0; from 1.06 +/- 0.10 to 0.75 +/- 0.11 nmol/g; P < 0.05), palmitoleate CoA (16:1; from 0.48 +/- 0.05 to 0.33 +/- 0.05 nmol/g; P = 0.07), oleate CoA (18:1; from 2.60 +/- 0.11 to 1.95 +/- 0.31 nmol/g; P < 0.05), linoleate CoA (18:2; from 1.81 +/- 0.26 to 1.38 +/- 0.18 nmol/g; P = 0.13), and linolenate CoA (18:3; from 0.27 +/- 0.03 to 0.19 +/- 0.02 nmol/g; P < 0.03) levels after acipimox treatment. Muscle stearate CoA (18:0) did not decrease after acipimox treatment. The increase in R(d) correlated strongly with the decrease in muscle palmityl CoA (r = 0.75, P < 0.05), oleate CoA (r = 0.76, P < 0.05), and total muscle LCFA-CoA (r = 0.74, P < 0.05) levels. Plasma adiponectin did not change significantly after acipimox treatment (7.9 +/- 1.8 vs. 7.5 +/- 1.5 microg/ml). These data demonstrate that the reduction in intramuscular LCFA-CoA content is closely associated with enhanced insulin sensitivity in muscle after a chronic reduction in plasma FFA concentrations in type 2 diabetic patients despite the lack of an effect on plasma adiponectin concentration." @default.
• W2160930691 created "2016-06-24" @default.
• W2160930691 creator A5008863193 @default.
• W2160930691 creator A5026337187 @default.
• W2160930691 creator A5027916227 @default.
• W2160930691 creator A5071246704 @default.
• W2160930691 creator A5072087217 @default.
• W2160930691 creator A5073917506 @default.
• W2160930691 creator A5089720468 @default.
• W2160930691 date "2005-11-01" @default.
• W2160930691 modified "2023-10-16" @default.
• W2160930691 title "Effect of a Sustained Reduction in Plasma Free Fatty Acid Concentration on Intramuscular Long-Chain Fatty Acyl-CoAs and Insulin Action in Type 2 Diabetic Patients" @default.
• W2160930691 cites W1524321743 @default.
• W2160930691 cites W1531062343 @default.
• W2160930691 cites W1587875569 @default.
• W2160930691 cites W1776131825 @default.
• W2160930691 cites W1964471496 @default.
• W2160930691 cites W1970409419 @default.
• W2160930691 cites W1977188464 @default.
• W2160930691 cites W1978248654 @default.
• W2160930691 cites W1981456793 @default.
• W2160930691 cites W1987680714 @default.
• W2160930691 cites W1990509911 @default.
• W2160930691 cites W1991795789 @default.
• W2160930691 cites W2001266437 @default.
• W2160930691 cites W2002888717 @default.
• W2160930691 cites W2007405015 @default.
• W2160930691 cites W2027670788 @default.
• W2160930691 cites W2031773477 @default.
• W2160930691 cites W2043106623 @default.
• W2160930691 cites W2046794153 @default.
• W2160930691 cites W2053770699 @default.
• W2160930691 cites W2059842910 @default.
• W2160930691 cites W2066736958 @default.
• W2160930691 cites W2072989847 @default.
• W2160930691 cites W2074390251 @default.
• W2160930691 cites W2083278430 @default.
• W2160930691 cites W2098842401 @default.
• W2160930691 cites W2099512289 @default.
• W2160930691 cites W2105912552 @default.
• W2160930691 cites W2108462699 @default.
• W2160930691 cites W2115433418 @default.
• W2160930691 cites W2115830695 @default.
• W2160930691 cites W2120282127 @default.
• W2160930691 cites W2124232607 @default.
• W2160930691 cites W2126317966 @default.
• W2160930691 cites W2130200187 @default.
• W2160930691 cites W2130850001 @default.
• W2160930691 cites W2132681327 @default.
• W2160930691 cites W2137842897 @default.
• W2160930691 cites W2139785109 @default.
• W2160930691 cites W2149703192 @default.
• W2160930691 cites W2150330027 @default.
• W2160930691 cites W2151025367 @default.
• W2160930691 cites W2152311269 @default.
• W2160930691 cites W2164895062 @default.
• W2160930691 cites W2169085802 @default.
• W2160930691 cites W2341717561 @default.
• W2160930691 cites W2511383158 @default.
• W2160930691 cites W2785468108 @default.
• W2160930691 cites W4205334134 @default.
• W2160930691 cites W4232051691 @default.
• W2160930691 cites W4234050533 @default.
• W2160930691 cites W4250266674 @default.
• W2160930691 doi "https://doi.org/10.2337/diabetes.54.11.3148" @default.
• W2160930691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16249438" @default.
• W2160930691 hasPublicationYear "2005" @default.
• W2160930691 type Work @default.
• W2160930691 sameAs 2160930691 @default.
• W2160930691 citedByCount "166" @default.
• W2160930691 countsByYear W21609306912012 @default.
• W2160930691 countsByYear W21609306912013 @default.
• W2160930691 countsByYear W21609306912014 @default.
• W2160930691 countsByYear W21609306912015 @default.
• W2160930691 countsByYear W21609306912016 @default.
• W2160930691 countsByYear W21609306912017 @default.
• W2160930691 countsByYear W21609306912018 @default.
• W2160930691 countsByYear W21609306912019 @default.
• W2160930691 countsByYear W21609306912020 @default.
• W2160930691 countsByYear W21609306912021 @default.
• W2160930691 countsByYear W21609306912022 @default.
• W2160930691 countsByYear W21609306912023 @default.
• W2160930691 crossrefType "journal-article" @default.
• W2160930691 hasAuthorship W2160930691A5008863193 @default.
• W2160930691 hasAuthorship W2160930691A5026337187 @default.
• W2160930691 hasAuthorship W2160930691A5027916227 @default.
• W2160930691 hasAuthorship W2160930691A5071246704 @default.
• W2160930691 hasAuthorship W2160930691A5072087217 @default.
• W2160930691 hasAuthorship W2160930691A5073917506 @default.
• W2160930691 hasAuthorship W2160930691A5089720468 @default.
• W2160930691 hasBestOaLocation W21609306911 @default.
• W2160930691 hasConcept C126322002 @default.
• W2160930691 hasConcept C134018914 @default.
• W2160930691 hasConcept C140985366 @default.
• W2160930691 hasConcept C171089720 @default.
• W2160930691 hasConcept C185592680 @default.
• W2160930691 hasConcept C2777180221 @default.
• W2160930691 hasConcept C2777391703 @default.

• next